Akebia Therapeutics Inc (AKBA)
1.86
-0.06
(-3.12%)
USD |
NASDAQ |
Nov 14, 16:00
1.865
0.00 (0.00%)
After-Hours: 20:00
Akebia Therapeutics Cash from Operations (Quarterly): -6.695M for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -6.695M |
| June 30, 2024 | -10.07M |
| March 31, 2024 | -19.43M |
| December 31, 2023 | -2.308M |
| September 30, 2023 | -7.167M |
| June 30, 2023 | 3.629M |
| March 31, 2023 | -17.54M |
| December 31, 2022 | -54.68M |
| September 30, 2022 | 33.80M |
| June 30, 2022 | -30.66M |
| March 31, 2022 | -21.62M |
| December 31, 2021 | -62.81M |
| September 30, 2021 | -56.27M |
| June 30, 2021 | -63.14M |
| March 31, 2021 | -70.75M |
| December 31, 2020 | -30.78M |
| September 30, 2020 | -27.24M |
| June 30, 2020 | 37.22M |
| March 31, 2020 | -89.59M |
| December 31, 2019 | -92.14M |
| September 30, 2019 | 10.99M |
| June 30, 2019 | -38.37M |
| March 31, 2019 | -137.93M |
| December 31, 2018 | -73.70M |
| Date | Value |
|---|---|
| September 30, 2018 | -12.46M |
| June 30, 2018 | 8.996M |
| March 31, 2018 | -20.33M |
| December 31, 2017 | -16.38M |
| September 30, 2017 | -54.62M |
| June 30, 2017 | 24.36M |
| March 31, 2017 | -9.528M |
| December 31, 2016 | 95.67M |
| September 30, 2016 | -28.24M |
| June 30, 2016 | -26.96M |
| March 31, 2016 | 17.43M |
| December 31, 2015 | -22.91M |
| September 30, 2015 | -9.031M |
| June 30, 2015 | -12.12M |
| March 31, 2015 | -8.347M |
| December 31, 2014 | -9.203M |
| September 30, 2014 | -5.603M |
| June 30, 2014 | -6.669M |
| March 31, 2014 | -6.008M |
| December 31, 2013 | -4.908M |
| September 30, 2013 | -2.938M |
| June 30, 2013 | -1.957M |
| March 31, 2013 | -1.530M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-92.14M
Minimum
Dec 2019
37.22M
Maximum
Jun 2020
-29.41M
Average
-24.43M
Median
Cash from Operations (Quarterly) Benchmarks
| Corcept Therapeutics Inc | 73.83M |
| Bioventus Inc | 10.32M |
| Eli Lilly and Co | 3.712B |
| NovaBay Pharmaceuticals Inc | -2.061M |
| Palatin Technologies Inc | -6.472M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.002M |
| Cash from Financing (Quarterly) | 1.223M |
| Free Cash Flow | -38.53M |
| Free Cash Flow Per Share (Quarterly) | -0.0318 |
| Free Cash Flow to Equity (Quarterly) | -7.021M |
| Free Cash Flow Yield | -10.17% |